Cargando…

Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion

Detalles Bibliográficos
Autores principales:	Zhang, Chunye, Yang, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637206/ https://www.ncbi.nlm.nih.gov/pubmed/34869507 http://dx.doi.org/10.3389/fmed.2021.789859

Ejemplares similares

The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma
por: Zhang, Chunye, et al.
Publicado: (2021)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

NAFLD-Associated HCC: Progress and Opportunities
por: Geh, Daniel, et al.
Publicado: (2021)

The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
por: Song, Qian, et al.
Publicado: (2022)

PPARs and Mitochondrial Metabolism: From NAFLD to HCC
por: Mello, Tommaso, et al.
Publicado: (2016)

NAFLD-Related HCC: Focus on the Latest Relevant Preclinical Models
por: Fang, Jing, et al.
Publicado: (2023)

Editorial: The heart of NAFLD
por: Chew, Nicholas W. S., et al.
Publicado: (2023)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)

A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?
por: Eldafashi, Nardeen, et al.
Publicado: (2021)

NAFLD and MAFLD as emerging causes of HCC: A populational study
por: Myers, Shuna, et al.
Publicado: (2021)

NAFLD as a risk factor for HCC: new rules of engagement?
por: Masuzaki, Ryota, et al.
Publicado: (2016)

Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes
por: Campani, Claudia, et al.
Publicado: (2020)

Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD
por: Jiang, Xiaofan, et al.
Publicado: (2020)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

New targets for NAFLD
por: Parlati, Lucia, et al.
Publicado: (2021)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Editorial: New Insights Into Understanding and Managing NAFLD
por: Escribano, Óscar, et al.
Publicado: (2021)

Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis
por: Garcia-Martinez, Irma, et al.
Publicado: (2020)

COVID-19 and MAFLD/NAFLD: An updated review
por: Nowroozi, Ali, et al.
Publicado: (2023)

The Implications of Noncoding RNAs in the Evolution and Progression of Nonalcoholic Fatty Liver Disease (NAFLD)-Related HCC
por: Rusu, Ioana, et al.
Publicado: (2022)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment
por: Xia, Ming-Feng, et al.
Publicado: (2019)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

NAFLD in the Elderly
por: Alqahtani, Saleh A, et al.
Publicado: (2021)

Treatments for NAFLD: State of Art
por: Mantovani, Alessandro, et al.
Publicado: (2021)

NAFLD: Mechanisms, Treatments, and Biomarkers
por: Nassir, Fatiha
Publicado: (2022)

Identification of 90 NAFLD GWAS loci and establishment of NAFLD PRS and causal role of NAFLD in coronary artery disease
por: Miao, Zong, et al.
Publicado: (2021)

The Role of Stem Cell Factor, Epidermal Growth Factor and Angiopoietin-2 in HBV, HCV, HCC and NAFLD
por: Radmanić, Leona, et al.
Publicado: (2022)

Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD
por: Marques, Vanda, et al.
Publicado: (2021)

Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD
por: Dibba, Pratima, et al.
Publicado: (2018)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

Restoration of CD4(+) T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC
por: Isbell, Madison, et al.
Publicado: (2022)

Risk of severe illness of COVID‐19 patients with NAFLD and increased NAFLD fibrosis scores
por: Yao, Renling, et al.
Publicado: (2021)

Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders
por: Turchinovich, Andrey, et al.
Publicado: (2018)

Age and Interleukin-15 Levels Are Independently Associated With Intima-Media Thickness in Obesity-Related NAFLD Patients
por: Tarantino, Giovanni, et al.
Publicado: (2021)

Comprehensive Analysis of NAFLD and the Therapeutic Target Identified
por: Wen, Weiheng, et al.
Publicado: (2021)

NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials
por: Hegazi, Omar E., et al.
Publicado: (2023)

A continuous-time Markov chain model of fibrosis progression in NAFLD and NASH
por: Meyer, Lyndsey F., et al.
Publicado: (2023)

ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy
por: Tian, Yuan, et al.
Publicado: (2019)

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
por: Martínez‐Arranz, Ibon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_psfm6lh2fi9tmqibmjr59a72v7